Good thoughts there. I am still casting my eye on the big...

Good thoughts there.

I am still casting my eye on the big picture. At a market cap of AUD$160m, I am buying a company that is disrupting an industry by selling products to faciliate the decentralisation of waste water treatment with MABR. IC was icing on the cake.

At this MC, it is fairly valued. But how about the potential? It's better than I first bought it as Emefcy. There is traction of sales in China, and SE Asian countries, and the Middle East with Nirobox. Yes, it has come full circle for me. I bought it as a concept with nothing but promises in 2017. Now, there is traction in the business. There are markets, noteworthily, in China, the biggest market in the world as far as I am concerned, where there is an embrace of new tech to leap frog the world. There is validation behind the technology. It has gone beyong the proof of concept stage. We just need to get the National SOE (China Rail, Three Gorges group) to make the bulk order to stamp its approval of the product nationally. When China stamps it, Vietnam, Cambodia, Philippines and rest of SEA will get more traction as we are seeing.

At this point of fragmented world politics, sadly what is good in China will not be seen favourably in the West. Hopefully the credentials of Israel will shine brighter than China. But I don't think Aspiral will get far in Europe where they will go for Dupont/Oxymem. If the US wakes up, it will stick to GE/Suez. We may not get the western markets. But there is still Africa and Asia where the greatest catchup is going to take place.

For a company that had negligible sales in SPS/MABR in 2017 to US$50m guidance this year if they can get the breakthrough to the national SOEs, it has come some ways. All IMHO, of course.